Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer

INTRODUCTION: Data of standard tyrosine kinase inhibitor (TKI) treatment outcome in next-generation sequencing (NGS)-identified ROS1-rearranged non-small-cell lung cancer (NSCLC) were rare. Thus, it is practical and necessary to evaluate the efficacy and influential factors of crizotinib in real-wor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Liang, Li, Yizhi, Xiao, Lili, Xiong, Yi, Liu, Li, Jiang, Wenjuan, Heng, Jianfu, Qu, Jingjing, Yang, Nong, Zhang, Yongchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199224/
https://www.ncbi.nlm.nih.gov/pubmed/30410351
http://dx.doi.org/10.2147/OTT.S176273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199224/
https://www.ncbi.nlm.nih.gov/pubmed/30410351
http://dx.doi.org/10.2147/OTT.S176273

Ejemplares similares